SYS-CON MEDIA Authors: Jayaram Krishnaswamy, Lori MacVittie, Gilad Parann-Nissany, Unitiv Blog, Bob Gourley

News Feed Item

Acquisitions, Appointments, FDA Approvals, and Study Milestones - Research Report on Jazz Pharmaceuticals, Boston Scientific, NuVasive, Endologix, and bluebird bio

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, December 25, 2013 /PRNewswire/ --


Today, Analysts' Corner announced new research reports highlighting Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ), Boston Scientific Corporation (NYSE: BSX), NuVasive, Inc. (NASDAQ: NUVA), Endologix Inc. (NASDAQ: ELGX), and bluebird bio, Inc. (NASDAQ: BLUE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Jazz Pharmaceuticals Public Limited Company Research Report

On December 19, 2013, Jazz Pharmaceuticals Public Limited Company (Jazz Pharmaceuticals), along with Gentium S.p.A (Gentium), announced that the two Companies have entered into a definitive agreement, under which a subsidiary of Jazz Pharmaceuticals will make a cash tender offer of $57.00 per share for all outstanding Gentium ordinary shares and American Depositary Shares. The Company stated that the transaction is valued at approximately $1 billion. Jazz Pharmaceuticals informed that Defitelio™ (defibrotide), a product of Gentium, was granted marketing authorization by European Commission in October 2013 for the treatment of severe hepatic veno-occlusive disease. Bruce Cozadd, Chairman and CEO of Jazz Pharmaceuticals, commented, "Incorporating Gentium into Jazz Pharmaceuticals is a strong strategic fit as Defitelio would diversify our development and commercial portfolio and complement our clinical experience in hematology/oncology and our expertise in reaching targeted physicians who treat serious medical conditions. Because Defitelio is already approved in the EU, the acquisition would add a new orphan product that has potential for short- and long-term revenue generation, high growth and expansion of our multi-national commercial platform." The Company stated that transaction is expected to be immediately accretive to its adjusted earnings per share. The Full Research Report on Jazz Pharmaceuticals Public Limited Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5fe3_JAZZ

--

Boston Scientific Corporation Research Report

On December 16, 2013, Boston Scientific Corporation (Boston Scientific) announced the election of David Roux as a Director, effective January 1, 2014. The Company added that Mr. Roux's appointment will fill a vacancy resulting from the Board's decision to increase the number of directors in the Board from ten to eleven. Boston Scientific informed that Mr. Roux is a co-founder and Senior Director of Silver Lake, a private equity firm focused on technology investing. Pete Nicholas, Chairman of Boston Scientific, commented, "I am excited to welcome David to our Board. I am confident that his wealth of experience and impressive background will benefit the company and our shareholders." The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5640_BSX

--

NuVasive, Inc. Research Report

On December 19, 2013, NuVasive, Inc. (NuVasive) announced the appointment of Frank Middeke as Managing Director of Germany, Austria, and Switzerland (DACH); Christoph Hoemberg as Director of Sales in Germany; and Constantino "Tino" Barros as Country Director of Spain. Paul Kosters, Senior Vice President of EMEA, NuVasive, stated, "I am exceptionally pleased to welcome Frank, Christoph, and Tino to the NuVasive Family. I look forward to their contributions as we collaborate to strengthen the NuVasive footprint in Europe, particularly in the DACH region. Based on the quality of the EMEA team that we now have in place, I am confident that we can work to drive toward market leadership in an area with considerable opportunity." The Full Research Report on NuVasive, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/c66c_NUVA

--

Endologix Inc. Research Report

On December 20, 2013, Endologix Inc. (Endologix) announced that it has received Investigational Device Exemption (IDE) approval from the US Food and Drug Administration (FDA) to initiate a pivotal clinical trial to evaluate the safety and effectiveness of the Nellix® EndoVascular Aneurysm Sealing System (EVAS) for the endovascular repair of infrarenal abdominal aortic aneurysms. John McDermott, Endologix Chairman and CEO, stated, "We are pleased to receive IDE approval from the FDA to begin this important clinical trial and look forward to collaborating with the investigators on this exciting new product. We believe Nellix has the potential to improve outcomes for patients and simplify AAA procedures for physicians. Based on the anticipated enrollment timeline and one-year follow up period, Nellix could potentially be available to physicians and patients in the U.S. in the second half of 2016." The Full Research Report on Endologix Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/2f8d_ELGX

--

bluebird bio, inc. Research Report

On December 2, 2013, bluebird bio, inc. (bluebird bio) announced that the first subject with beta-thalassemia major has been enrolled in its phase 1/2 HGB-205 study in France. According to bluebird bio, the first subject has already undergone infusion with its LentiGlobin drug product in an autologous hematopoietic stem cell transplantation. Dave Davidson, MD, bluebird bio's Chief Medical Officer, commented, "It is very gratifying for our research, manufacturing and development teams to see their efforts to improve the potency and scalability of our product platform finally reach the clinic for patients with this life threatening disease. This milestone brings us closer towards realizing our vision of making hope a reality for patients with limited therapeutic options." The Full Research Report on bluebird bio, inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/91eb_BLUE

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
  5. For any urgent concerns or inquiries, please contact us at [email protected].
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.